Assembly Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Assembly Biosciences, Inc. (ASMB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2022-03-11
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-09-30 was $1.00M, a 11.11% increase year-over-year.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-06-30 was $800.00K, a 100.00% increase year-over-year.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-03-31 was $200.00K, a 33.33% decline year-over-year.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $2.00M, a 60.00% decline from fiscal 2019.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $5.00M, a 83.92% decline from fiscal 2018.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $31.10M, a 217.35% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-11 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $1.00M derived: sum of 2 quarters · filed 2022-03-11 | $1.80M derived: sum of 3 quarters · filed 2022-03-11 | $2.00M 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.80M derived: sum of 2 quarters · filed 2021-11-04 | $2.00M 10-Q · filed 2021-11-04 | $5.40M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.00M 10-Q · filed 2021-08-05 | $4.40M derived: sum of 3 quarters · filed 2021-08-05 | $5.30M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-06 | $3.60M derived: sum of 2 quarters · filed 2021-05-06 | $4.50M derived: sum of 3 quarters · filed 2021-05-06 | $4.90M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.30M derived: sum of 2 quarters · filed 2021-02-25 | $4.70M derived: sum of 3 quarters · filed 2021-02-25 | $5.00M 10-K · filed 2021-02-25 |
| 2019-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.30M derived: sum of 2 quarters · filed 2020-11-05 | $1.60M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $700.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $300.00K 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $31.10M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $9.80M 10-K · filed 2020-03-04 | |||
| 2015-09-30 | -$394.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$48.19K derived: sum of 2 quarters · filed 2015-11-09 | $91.94K 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $346.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $486.40K 10-Q · filed 2015-08-13 | ||
| 2015-03-31 | $140.13K 10-Q · filed 2015-05-08 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-14 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $0.00 derived: sum of 2 quarters · filed 2013-11-12 | $0.00 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 | ||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |